Leadership
Solara Active Pharma Seeks Shareholder Vote on CEO Sandeep Rao's Pay Revision and New Incentive Plans
By News Desk ·
Key takeaways
- Solara Active Pharma Sciences has proposed raising Managing Director and CEO Sandeep Shashikantha Rao's fixed remuneration from ₹3.25 crore to ₹4.00 crore per annum.
- Whole Time Director Mohanraj Sanjeevi's fixed pay is proposed to rise from ₹85 lakh to ₹95 lakh per annum, with his variable pay unchanged at ₹15 lakh.
- Remote e-voting on the special resolutions runs from November 18 to December 17, 2026, with results expected on or before December 21, 2026.
Solara Active Pharma Sciences has begun a postal ballot asking shareholders to approve revised pay for Managing Director and CEO Sandeep Shashikantha Rao and Whole Time Director Mohanraj Sanjeevi, ScanX reported on November 17, 2026. Rao's fixed remuneration is proposed to rise from ₹3.25 crore to ₹4.00 crore per annum.
What the Solara Active Pharma Proposals Cover
The revisions take effect from July 1, 2026. Rao's annual variable pay is set at ₹1.50 crore, up from ₹0.75 crore, and he becomes eligible for a long-term incentive plan with an aggregate cost not exceeding ₹5.00 crore, structured over four years with payouts extending beyond his current term ending February 20, 2028.
Sanjeevi's fixed remuneration is proposed to increase from ₹85 lakh to ₹95 lakh per annum, while his annual variable pay stays at ₹15 lakh. He will also be eligible for a long-term incentive plan capped at ₹40 lakh during his remaining tenure up to December 31, 2028. Both executives retain eligibility for employee stock options granted under the ESOP Plan 2024.
The board recommended the revisions following a performance review by the Nomination and Remuneration Committee. The postal ballot notice was dispatched electronically on November 17, 2026, to members registered as of November 13, 2026.
Solara Active Pharma's Financial Backdrop
According to akta.pro company records, Solara Active Pharma reported full-year FY26 revenue of Rs. 1368.98 crore, up 6.64% year-on-year, and Q4 FY26 revenue of Rs. 387.29 crore, up 41.86% year-on-year. The same records list six manufacturing facilities and two R&D centres across India, and a February 2019 private equity round of $30 million led by TPG Growth.
ScanX reported that the company's standalone net loss was ₹7.24 crore in FY26, compared with a loss of ₹1.08 crore in FY25, and that revenue rose from ₹1,292.90 crore in FY25 to ₹1,374.87 crore in FY26. The company attributes the losses primarily to weakness in its commodity Ibuprofen business amid global oversupply and pricing pressure, while noting that its core API business remains profitable.
Earlier Solara Active Pharma Leadership Moves
In July 2026, Solara Active Pharma appointed Ajit Manocha as Chief Information Officer effective August 10, 2026, following board approval, ScanX reported. The company then postponed his joining date by one week to August 17, 2026, citing personal reasons, ScanX reported in August 2026.
On August 28, 2026, the company said the Income Tax Department reduced a ₹161.92-crore tax demand against it to nil after correcting the computation, CNBCTV18 reported.
When Solara Active Pharma's Vote Closes
Remote e-voting through the Central Depository Services (India) Limited facility opened on November 18, 2026, and closes at 5:00 pm on December 17, 2026. Results are expected to be declared on or before December 21, 2026.